Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels in adults with hypercholesterolemia or mixed dyslipidemia.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy combines simvastatin and ezetimibe to treat disorders of lipid metabolism.

- Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol levels. - Mixed dyslipidemia: improves overall lipid profile by lowering LDL and triglycerides while raising HDL. - Primary prevention of cardiovascular events: lowers the risk of heart attack and stroke in patients with elevated cholesterol.

Inegy may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal discomfort: including nausea, abdominal pain, or diarrhea. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: asymptomatic increase in ALT/AST. - Dizziness: transient light‑headedness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal failure. - Acute liver injury: marked elevation of liver enzymes or jaundice. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Myopathy: muscle weakness with elevated CK levels. - Hepatotoxicity: clinically significant liver dysfunction. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential adverse events.

- Liver function monitoring: check baseline ALT/AST and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained muscle pain, tenderness, or weakness. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors and gemfibrozil. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; generally avoided. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Inegy interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase simvastatin exposure. - Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates both simvastatin and ezetimibe concentrations. - HIV protease inhibitors (e.g., ritonavir): potentiate statin levels. - Grapefruit juice: enhances simvastatin plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect; monitor INR. - Digoxin: potential increase in serum digoxin concentration. - Niacin: additive risk of myopathy. - Antacids containing aluminum or magnesium: may affect ezetimibe absorption. - Other fibrates (except gemfibrozil): monitor for muscle toxicity.